Product name: Vicenin II
Synonym name: 6,8-Di-C-glucopyranosylapigenin; 6,8-Di-C-glucosylapigenin
Catalogue No.: BP1605
Cas No.: 23666-13-9
Formula: C₂₇H₃₀O₁₅
Mol Weight: 594.522
Botanical Source: Constit. of the wood of Vitex lucens, and of lemons Citrus limon, and of quince pips (Cydonia oblonga), Urtica circularis and of many other plant spp
Physical Description: Yellow powder
Type of Compound: Flavonoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.

Descriptions:
Vicenin-2 (VCN-2), an active constituent of the medicinal herb Ocimum Sanctum Linn or Tulsi, it can effectively induce anti-proliferative, anti-angiogenic and pro-apoptotic effect in CaP cells (PC-3, DU-145 and LNCaP) irrespective of their androgen responsiveness or p53 status;VCN-2 in combination with docetaxel (DTL) synergistically inhibited the growth of prostate tumors in vivo with a greater decrease in the levels of AR, pIGF1R, pAkt, PCNA, cyclin D1, Ki67, CD31, and increase in E-cadherin; it could as a single agent and in combination with DTL in carcinoma of prostate (CaP). [1]
Vicenin-2 has potential anti-inflammatory activity, can modify LPS-induced total nitrite and TNF-α production, in addition to the LPS-induced translocation of the nuclear factor NF-κB.[2]
vicenin-2 and scolymoside, can suppress high-glucose (HG)-induced vascular inflammatory processes in human umbilical vein endothelial cells (HUVECs) and mice, HG-induced vascular inflammatory responses are critical events underlying the development of various diabetic complications; therefore, suggests that vicenin-2 and scolymoside have significant therapeutic benefits against diabetic complications and atherosclerosis.[3]
Vicenin-2 or scolymoside can reduce cecal ligation and puncture (CLP)-induced septic mortality and pulmonary injury, indicate that vicenin-2 and scolymoside could be a potential therapeutic agent for treatment of various severe vascular inflammatory diseases via inhibition of the TGFBIp signaling pathway.[4]
Vicenin-2 has antithrombotic and antiplatelet activities.[5]

References:
[1] Nagaprashantha L D, Vatsyayan R, Singhal J, et al. Biochem Pharmacol, 2011, 82(9):1100-9.
[2] Marrassini C, Davicino R, Acevedo C, et al. J Nat Prod, 2011, 74(6):1503-7.
[3] Ku S K, Bae J S. Can J Physiol Pharm, 2016, 3(1): 287-95.
[4] Lee W, Ku S K, Bae J S. Inflammation, 2015, 38(6):2166-77.
[5] Lee W, Bae J S. Blood Coagul Fibrin, 2015, 26(6):628-34.
[6] Qin L U. China Pharmacy, 2015(30):4271-3.

HPLC of  Vicenin II